Mr. Zeeshan Saeed reports

FSD PHARMA ADDS FORMER CELSIUS HOLDINGS CEO GERRY DAVID TO BOARD OF ADVISORS

FSD Pharma Inc. has appointed Gerry David to the FSD Pharma advisory board. Mr. David is best known for his five-year tenure as chief executive officer at zero-calorie fitness drink maker Celsius Holdings Inc. where he spearheaded a turnaround that resulted in a global sales explosion, influx of capital from notable strategic investors and a rise in market capitalization that increased shareholder value 35-fold by exceeding $9-billion.

"I have seen countless products throughout my career and I can honestly say that I have never seen anything as unique and disruptive as the product FSD Pharma is developing to counteract alcohol intoxication and misuse," commented Mr. David. "I am excited to begin working with the entire team on development strategy and welcome the opportunity to lend any resources and experiences I have to help achieve the goal of a commercialized product in the future," added Mr. David.

"Gerry is a legend in the business world and his insight is tantamount to the recent addition of Kevin Harrington to our advisory board [see press release dated Feb. 28, 2023]," said Anthony Durkacz, interim chief executive officer of FSD Pharma. "Gerry's successes in sales and marketing, supply chain management and value creation are rarely paralleled. He will be invaluable to guidance of our entire pipeline and, more precisely, become intimately involved with the strategic planning, launch and operations of our new alcohol misuse R&D [research and development] program. We welcome him to the team."

Mr. David is a solution-focused entrepreneur, leader and board member with more than 40 years of success across the consumer products, manufacturing and high-tech industries. Leveraging extensive experience leading five comprehensive turnarounds of both public and private companies with global scopes spanning 72 countries, he is a valuable asset for start-up or established companies looking to drive long-term, sustainable growth. His broad areas of expertise include sales and marketing, operations management, financial analysis, capital raising, supply chain management, M&A (mergers and acquisitions), regulatory, and strategic planning. In recognition of his professional achievements, he was one of only 25 gold winners in the prestigious 2016 CEO World Awards and was selected as the leader in the CEO of the Year category.

Throughout his executive career, Mr. David has held leadership positions at organizations, including Celsius Holdings, Vitarich Labs, Home Shopping Network Direct, and his consulting firm Gerry David & Associates LLC, where he currently serves as chief executive officer. He has been responsible for leading the turnaround of Celsius Holdings, a beverage company on the verge of going out of business, driving five consecutive years of record revenue, increasing shareholder value by 35 times, establishing a subsidiary in Hong Kong, launching products in Asia, South America, Europe and the Middle East, and establishing manufacturing in Germany, China and the United States. Mr. David began his career by founding a systems integration company specializing in the hospitality industry, growing the organization to offices in six states prior to its sale to a public entity.

About FSD Pharma Inc.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. FSD BioSciences Inc., a wholly owned subsidiary, is focused on pharmaceutical research and development of its lead compound, FSD201, a proprietary ultramicronized PEA (palmitoylethanolamide) formulation, for the treatment of inflammatory diseases. Lucid Psychss Inc., a wholly owned subsidiary, is focused on the research and development of its lead compounds, Lucid-Psych and Lucid-MS. Lucid-Psych is a molecular compound identified for the potential treatment of mental health disorders, and, expanding this category, the company is investigating other products addressing acute medical needs due to the abuse of drugs such as alcohol. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

We seek Safe Harbor.